GLP-1 receptor agonists like semaglutide have transformed weight loss treatment, but patients with Crohn's disease face unique safety questions
So staying away from gluten, sugar, hydrogenated oils, and animal products that contain antibiotic residue are crucial
While some individuals may experience positive outcomes with lipotropic injections, the success of any weight loss effort at NY Medical Weight Loss is built on the foundation of sustainable lifestyle changes
What Affects How Quickly You Feel Better
This may involve adjusting diabetes management strategies, controlling blood pressure, and in some cases, discontinuing the GLP-1 medication

enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)
